公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US12097206B2

公开(公告)日：2024-09-24

申请号：US17667136

申请日：2022-02-08

申请人： KATHOLIEKE UNIVERSITEIT LEUVEN ,  UNIVERSITY HOSPITAL ANTWERP

发明人： Berten Ceulemens ,  Lieven Lagae

IPC分类号： A61K31/5513 ,  A61K31/135 ,  A61K31/137 ,  A61K31/19 ,  A61K31/36 ,  A61K31/551 ,  A61K45/06 ,  C12Q1/6883

CPC分类号： A61K31/5513 ,  A61K31/135 ,  A61K31/137 ,  A61K31/19 ,  A61K31/36 ,  A61K31/551 ,  A61K45/06 ,  C12Q1/6883 ,  C12Q2600/156 ,  A61K31/137 ,  A61K2300/00

摘要： A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.

公开(公告)号：US20240308960A1

公开(公告)日：2024-09-19

申请号：US18563776

申请日：2022-05-26

申请人： Sumitomo Pharma Co., Ltd.

发明人： Masafumi KOMIYA ,  Shunichiro UESUGI ,  Eiji IDEUE ,  Shoukou LEE ,  Daisuke TANAKA ,  Yuta FUNAKOSHI

IPC分类号： C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

CPC分类号： C07D211/22 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/55 ,  A61K31/551 ,  C07D211/16 ,  C07D211/26 ,  C07D211/46 ,  C07D221/04 ,  C07D223/16 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

摘要： The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin receptor type 2, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing a disease such as narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome.

公开(公告)号：US20240300964A1

公开(公告)日：2024-09-12

申请号：US18291432

申请日：2022-07-22

申请人： Leidos Biomedical Research, Inc. ,  Lawrence Livermore National Security, LLC ,  TheRas, Inc.

发明人： Bin Wang ,  Rui Xu ,  Eli Wallace ,  Zuhui Zhang ,  David Michael Turner ,  Anna Elzbieta Maciag ,  Dhirendra Kumar Simanshu ,  Albert Hay Wah Chan ,  Tao Liao ,  Christopher John Brassard ,  Yue Yang ,  Paola Bisignano ,  Felice Lightstone

IPC分类号： C07D487/10 ,  A61K31/517 ,  A61K31/551 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D519/00

CPC分类号： C07D487/10 ,  A61K31/517 ,  A61K31/551 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D519/00

摘要： Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12C mutation) and treating diseases or disorders such as cancers in subjects in need thereof.

公开(公告)号：US20240299408A1

公开(公告)日：2024-09-12

申请号：US18549237

申请日：2021-01-08

申请人： Woolsey Pharmaceuticals, Inc.

发明人： Thomas MACALLISTER ,  Sven JACOBSON

IPC分类号： A61K31/551

CPC分类号： A61K31/551

摘要： The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.

公开(公告)号：US12084472B2

公开(公告)日：2024-09-10

申请号：US17185653

申请日：2021-02-25

申请人： Ardelyx, Inc.

发明人： Jason G. Lewis ,  Michael Robert Leadbetter ,  Jeremy Caldwell ,  Dean Dragoli ,  Noah Bell ,  Jeffrey W. Jacobs ,  Patricia Finn ,  Rakesh Jain ,  Tao Chen ,  Matthew Siegel

IPC分类号： A61K31/444 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/553 ,  A61K31/706 ,  A61K45/06 ,  C07B59/00 ,  C07C409/12 ,  C07D213/30 ,  C07D213/38 ,  C07D213/80 ,  C07D213/81 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/08 ,  C07H15/04 ,  C07H15/18 ,  C07H15/234 ,  C07H15/26

CPC分类号： C07H15/26 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/553 ,  A61K31/706 ,  A61K45/06 ,  C07B59/002 ,  C07C409/12 ,  C07D213/30 ,  C07D213/38 ,  C07D213/80 ,  C07D213/81 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/08 ,  C07H15/04 ,  C07H15/18 ,  C07H15/234 ,  C07B2200/05

摘要： The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula:






where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

公开(公告)号：US12083185B2

公开(公告)日：2024-09-10

申请号：US17284562

申请日：2019-10-11

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Jingjing Sun ,  Song Li

IPC分类号： A61K47/69 ,  A61K9/107 ,  A61K31/12 ,  A61K31/138 ,  A61K31/337 ,  A61K31/366 ,  A61K31/404 ,  A61K31/405 ,  A61K31/436 ,  A61K31/506 ,  A61K31/551 ,  A61K31/7068 ,  A61K38/13 ,  A61K47/54 ,  A61K47/58 ,  A61K47/60

CPC分类号： A61K47/6907 ,  A61K9/1075 ,  A61K31/12 ,  A61K31/138 ,  A61K31/337 ,  A61K31/366 ,  A61K31/404 ,  A61K31/405 ,  A61K31/436 ,  A61K31/506 ,  A61K31/551 ,  A61K31/7068 ,  A61K38/13 ,  A61K47/54 ,  A61K47/542 ,  A61K47/58 ,  A61K47/60

摘要： A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer.

公开(公告)号：US20240287078A1

公开(公告)日：2024-08-29

申请号：US18565009

申请日：2022-06-09

申请人： Redx Pharma PLC

发明人： Clifford D. Jones ,  Inder Bhamra ,  James Ryan

IPC分类号： C07D487/04 ,  A61K31/517 ,  A61K31/541 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61K31/517 ,  A61K31/541 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  C07D519/00

摘要： This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.

公开(公告)号：US20240285645A1

公开(公告)日：2024-08-29

申请号：US18471508

申请日：2023-09-21

申请人： Gilead Sciences, Inc.

发明人： Romas Geleziunas ,  Joseph E. Hesselgesser

IPC分类号： A61K31/551 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/527 ,  A61K31/5365 ,  A61K31/5377 ,  A61K31/675 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06

CPC分类号： A61K31/551 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/527 ,  A61K31/5365 ,  A61K31/5377 ,  A61K31/675 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/55511

摘要： Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula II:






and pharmaceutically acceptable salts thereof, useful in treating HIV infections.

公开(公告)号：US20240279241A1

公开(公告)日：2024-08-22

申请号：US18562608

申请日：2022-05-27

申请人： Redx Pharma PLC

发明人： Clifford D. Jones ,  Inder Bhamra

IPC分类号： C07D519/00 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554

CPC分类号： C07D519/00 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554

摘要： This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may therefore be used in treating conditions mediated by KRAS proteins. For example, the compounds may be used in treating cancer.